tldrdailynews.com logo

Ifinatamab Deruxtecan Shows Promising Results in Small Cell Lung Cancer Trial

1 min read
Source: Merck.com
Ifinatamab Deruxtecan Shows Promising Results in Small Cell Lung Cancer Trial
Photo: Merck.com
TL;DR

The Phase 2 IDeate-Lung01 trial showed that the drug ifinatamab deruxtecan achieved a 48.2% objective response rate in previously treated extensive-stage small cell lung cancer patients, with promising safety and efficacy data supporting further regulatory discussions.

Topics:businesshealthcare#clinical-trial#daiichi-sankyo#healthcare#ifinatamab-deruxtecan#merck#small-cell-lung-cancer
Share this article
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial  Merck.comView Full Coverage on Google News

Want the full story? Read the original reporting

Read on Merck.com